BASF Launches Two Precision Collagen Actives — Here's What Shipped
BASF used in-cosmetics Global 2026 to launch two new collagen-targeting actives — one a precision peptide, one a bio-identical Collagen III fragment. Here is what the ingredients actually do.
What launched
BASF announced two new cosmetic actives at in-cosmetics Global in Paris in mid-April, both aimed at collagen support. According to the company's release and follow-up reporting in Cosmetics & Toiletries, the first is NeoHelix Regenerate, a "precision peptide" developed in partnership with US start-up 3Helix using collagen-hybridising peptide technology originally developed for medical applications. The second is SkinNexus Collag3n, a bio-identical Collagen III fragment produced by vegan yeast fermentation, developed with Bota Biosciences using AI-driven biomanufacturing.
NeoHelix Regenerate was awarded first place in the BSB Innovation Award's Cosmetics / Raw Materials category. BASF's clinical data on SkinNexus Collag3n claims measurable improvements in skin tonicity and reductions in fine lines after four weeks; the in vitro work shows increases in Collagen I, III, and V markers in a 3D dermis model.
What is genuinely new here
Two things are worth noting. First, the collagen-hybridising peptide technology is unusual: it is designed to dock with already-damaged collagen and signal repair to that specific area, rather than diffusely stimulating new synthesis. If the mechanism translates from lab to leave-on cosmetics, it represents a different therapeutic approach than most "collagen support" claims.
Second, SkinNexus Collag3n's manufacturing is the news. Bio-identical recombinant collagen fragments produced by yeast fermentation are not new in principle, but cost and scale have been the blockers. BASF and Bota's positioning emphasises industrial scalability — which is to say, this is engineered to make precision collagen actives affordable enough for mainstream brands, not only luxury.
What to keep in proportion
Two reality checks. First: these are ingredients, not products. You cannot buy NeoHelix Regenerate. You can only buy finished cosmetics that contain it, at concentrations decided by the brand. Inclusion at the bottom of an INCI list is meaningfully different from inclusion at a clinically tested level near the top.
Second: BASF's clinical data is supplier data. It tends to be well-conducted but it is also done to support sales. Independent replication on finished products is what will tell us whether either active does what the launch materials suggest. Watch for that, not the press release.
Why this announcement matters anyway
Even if these specific ingredients turn out to be modest performers in finished products, the launch is a signal: the industry's collagen story is moving from generic "stimulators" toward targeted approaches with specifiable mechanisms — fragment delivery, hybridisation with damaged collagen, biotech-produced human-identical sequences. That is genuinely different from where the category was five years ago, when "collagen-boosting" mostly meant adding peptides without much specificity.
Whether any of this beats a good retinoid plus consistent sunscreen for skin appearance over a decade is a separate question. (It does not. Not yet, anyway.)
BASF's launches are real progress on a specific ingredient class. They are not, on their own, a reason to redesign your routine.